Literature DB >> 8856855

Micturition disturbance in acute transverse myelitis.

R Sakakibara1, T Hattori, K Yasuda, T Yamanishi.   

Abstract

In ten patients with acute transverse myelitis (ATM), seven patients had urinary retention, and the other three patients had difficulty in voiding within 1 month from the onset of the disease. Five of the patients with retention became able to urinate. After the mean follow-up period of 40 months, nine still had urinary symptoms including difficulty in voiding in five and urinary frequency, urgency and incontinence in four patients. Four patients had urinary disturbance as the sole sequel of ATM. Urodynamic studies performed on nine patients revealed that all of the three patients with the urgent incontinence had detrusor hyperreflexia, all of the four patients with retention had an areflexic cystometrogram as well as sphincter hyperreflexia, and three of five patients with voiding difficulty had detrusor-sphincter dyssynergia. An areflexic cystometrogram tended to change to a low compliance bladder, followed by detrusor hyperreflexia or a normal cystometrogram. Analysis of the motor unit potentials of the external sphincter revealed that two of the three patients had high amplitude or polyphasic neurogenic changes. Supranuclear as well as nuclear types of parasympathetic and somatic nerve dysfunctions seemed to be responsible for micturition disturbance in our patients with ATM.

Entities:  

Mesh:

Year:  1996        PMID: 8856855     DOI: 10.1038/sc.1996.82

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  11 in total

1.  Neurological and functional recovery in acute transverse myelitis patients with inpatient rehabilitation and magnetic resonance imaging correlates.

Authors:  A Gupta; S N Kumar; A B Taly
Journal:  Spinal Cord       Date:  2016-03-01       Impact factor: 2.772

2.  Bladder dysfunction in acute transverse myelitis: magnetic resonance imaging and neurophysiological and urodynamic correlations.

Authors:  J Kalita; S Shah; R Kapoor; U K Misra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

Review 3.  Neurogenic lower urinary tract dysfunction in multiple sclerosis, neuromyelitis optica, and related disorders.

Authors:  Ryuji Sakakibara
Journal:  Clin Auton Res       Date:  2018-08-03       Impact factor: 4.435

4.  Acute urinary retention due to benign inflammatory nervous diseases.

Authors:  Ryuji Sakakibara; Tomonori Yamanishi; Tomoyuki Uchiyama; Takamichi Hattori
Journal:  J Neurol       Date:  2006-05-06       Impact factor: 6.682

Review 5.  Demyelinating disorders: update on transverse myelitis.

Authors:  Chitra Krishnan; Adam I Kaplin; Carlos A Pardo; Douglas A Kerr; Sanjay C Keswani
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 6.030

6.  Urodynamic profile in acute transverse myelitis patients: Its correlation with neurological outcome.

Authors:  Anupam Gupta; Sushruth Nagesh Kumar; Arun B Taly
Journal:  J Neurosci Rural Pract       Date:  2017 Jan-Mar

Review 7.  Longitudinally extensive transverse myelitis after Covid-19 vaccination: case report and review of literature.

Authors:  Seyed Farzad Maroufi; Fereshteh Naderi Behdani; Fatemeh Rezania; Samaneh Tanhapour Khotbehsara; Zahra Mirzaasgari
Journal:  Hum Vaccin Immunother       Date:  2022-03-03       Impact factor: 4.526

Review 8.  Acute Transverse Myelitis in Children, Literature Review.

Authors:  Azita Tavasoli; Aidin Tabrizi
Journal:  Iran J Child Neurol       Date:  2018

9.  Effects of electroacupuncture on bladder and bowel function in patients with transverse myelitis: a prospective observational study.

Authors:  Jiani Wu; Yanjun Cheng; Zongshi Qin; Xiaoxu Liu; Zhishun Liu
Journal:  Acupunct Med       Date:  2018-06-16       Impact factor: 2.267

Review 10.  Acute disseminated encephalomyelitis: clinical and pathogenesis features.

Authors:  Farshid Noorbakhsh; Richard T Johnson; Derek Emery; Christopher Power
Journal:  Neurol Clin       Date:  2008-08       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.